A batch of "made in Xiamen" biomedical products sell well in the world

Biology and new medicine industry is one of the ten hundred billion industry chains (clusters) that our city strives to build Xiamen's biological and new pharmaceutical industry has many initiatives There is no need to "fly" abroad to vaccinate cervical cancer vaccine The reporter recently learned from the Municipal Science and Technology Bureau that the cervical cancer vaccine developed by a company in Xiamen has entered phase III clinical practice, which can prevent 70% of cervical cancer types It is the first cervical cancer vaccine in China In addition, Xiamen biological and new pharmaceutical industry has many initiatives and takes the lead At the same time, it has the world's largest coenzyme Q10 manufacturer, the first choice of bone and joint protection products of the national volleyball team, etc From 2011 to 2014, the total industrial output value of Xiamen biological and new pharmaceutical industry increased by more than 31% annually, showing a good and rapid development trend Last year, there were 546 biological and new pharmaceutical enterprises in the city, with a total industrial output value of 28 billion yuan and a total industrial sales revenue of more than 40 billion yuan, accounting for about 50% of Fujian Province The brilliant report card is inseparable from the high attention of Xiamen Municipal Committee and government - biology and new medicine industry is one of the most promising high-tech industries, and also one of the ten hundred billion industrial chains (clusters) that the Municipal Committee and government strive to build In recent years, based on the "beautiful Xiamen" industrial upgrading action plan, the Municipal Bureau of science and technology has made great efforts to build Xiamen biomedical port, constantly optimize the industrial innovation and development environment, fully promote the high-end and large-scale development of the biological and new pharmaceutical industry, and strive to make Xiamen biomedical port a national biomedical industry demonstration area Xiamen Municipal Science and Technology Bureau also supported 271 projects in this field during the 12th Five Year Plan period, with a subsidy of 285 million yuan and a social investment of 1.368 billion yuan, to support the continuous optimization of innovation environment and customized support policies for the development of biology and new medicine, so as to provide "blood and oxygen" for the growth of enterprises To build a first-class highland of biology and new medicine industry, a good environment is the key In recent years, as the leading unit of cultivation and development, the Municipal Science and Technology Bureau has cooperated with the municipal development and Reform Commission, the Municipal Finance Bureau and the Municipal Food and drug administration And Haicang District government and other relevant units, under the leadership of the municipal Party committee and the municipal government, continue to innovate the working mechanism, issue operational industrial development policies, promote industrial agglomeration, actively and continuously promote the rapid development of biological and new pharmaceutical industry in our city, and improve the ability of new drug creation In order to find a "balance point" between transformation, upgrading and growth rate, with a strong biological and new pharmaceutical foundation, our city has incorporated the biological and new pharmaceutical industry into one billion industrial chain (Group), established the "leading group for promoting the development of biological and new pharmaceutical industry in Xiamen", prepared the development plan of biological and new pharmaceutical industry in Xiamen, and defined the industrial focus and development party Xianghe goal, issued "several measures to speed up the development of biology and new medicine industry in Xiamen", and continuously strengthened the support for biology and new medicine industry in terms of technological innovation, achievement transformation and industrialization, investment attraction, market development, etc In view of the biological and new pharmaceutical industry, our city has also specially issued a package of preferential policies to protect enterprises in all aspects Specifically, it includes: major projects such as self-developed and transferred biological products and drugs, 1-6 traditional Chinese medicine, 1-4 chemicals, and class III medical devices, each of which will be subsidized with 20 million yuan; biological and new pharmaceutical enterprises that apply for international certification, carry out international multi center clinical research of biological products or register abroad will be subsidized with 6 million yuan; and "multiplier" will be organized and implemented Plan ", select potential enterprises with advantages, focus on Cultivation and support, customize the" enterprise multiplication development plan "for enterprises, and help enterprises to double their output value after 2-3 years of efforts As the leading unit for the cultivation and development of biological and new pharmaceutical industry in Xiamen, the Municipal Science and Technology Bureau strongly supports the biological and new pharmaceutical industry in Xiamen to enhance its independent innovation capacity through the Municipal Science and technology plan project During the 12th Five Year Plan period (2011-2014), 271 projects in the field of biological and new medicine were supported, with the amount of support of 285 million yuan, and the social investment of 1.368 billion yuan was driven, with key support Development of new products and upgrading of products By giving full play to the technical advantages of universities and scientific research institutions and constantly improving the independent innovation ability of enterprises, Xiamen's new drug creation ability has been continuously strengthened Since the 11th five year plan, there are 12 first-class new drugs declared or entered clinical trials in the city, ranking first in Fujian Province The city has set up 26 scientific and technological innovation and public service platforms, which have been built and are under construction, and has built a relatively complete industrial development system of "innovative R & D - Incubator - pilot test base - Industrial Park" Located in Haicang and with a planned construction area of 10 square kilometers, Xiamen biomedical port is a vivid case of biology and new pharmaceutical industry in our city At present, a "one hundred thousand" leap development pattern has been formed here, namely: 10000 square meters of biomedical incubator; 100000 square meters of pilot production industrialization base; 1 million square meters of biomedical park; 10 million square meters of biomedical port In 2014, Haicang District, the core area of Xiamen biomedical port, had 190 biological and new pharmaceutical enterprises, achieving a total industrial output value of 12.5 billion yuan, accounting for 44.6% of the city's total, and the industrial agglomeration effect was initially apparent Innovation needs to speed up the construction of public service platform Starting from small and micro enterprises, the city has actively set up 26 science and technology innovation and public service platforms, including key technology platforms for viral drug target research and drug resistance evaluation, cross-strait molecular pathology technology center, pilot scale test base for marine biotechnology industrialization, etc., with scientific and technological capital investment of 265 million yuan and social science and technology investment of 1.637 billion yuan Yuan, built a relatively perfect industrial development system of "innovation and development incubator pilot test base industrial park" At present, our city has four national R & D and innovation platforms, five national pilot and Industrialization Bases (platforms), and Xiamen biomedical incubator has been rated as the "National Science and technology enterprise incubator" in 2014, becoming the only national biomedical science and technology enterprise professional incubator in Fujian Province The goal is to achieve 100 billion yuan of output value two years in advance It is expected to reach 2020 and 2018 in advance The overall development goal of "1111" is to build a national level biomedical industry base, 10 national level scientific research platforms, cultivate more than 100 billion yuan of enterprises, and achieve 100 billion yuan of total output value Next, with biomedicine as the core, our city will vigorously develop bio manufacturing, bio agriculture and bio service industries, strive to build a deep integration of "government, industry, learning, research, capital, and use" and a technological innovation system with enterprises as the main body, and accelerate talent concentration, technology concentration, project accumulation, capital accumulation and industrial agglomeration Specifically, our city will continue to increase investment in science and technology, enhance the innovation and development ability of enterprises; cultivate backbone enterprises including Wantai Canghai, Tebao biology, unnamed medicine, etc., implement the development strategy of industrial "small giant", support them to become stronger and bigger, and encourage small and medium-sized enterprises of biology and new medicine to settle in Haicang to achieve cluster development; continue to implement the "multiplier plan" To support the leapfrog development of enterprises; to strengthen deep-seated scientific and technological exchanges and cooperation in Taiwan's industry, strengthen cross-strait cooperation in the field of medicine and health, build Taiwan's Biotechnology Industrial Park, and make every effort to transform and introduce 219 scientific research achievements in the field of biotechnology in Taiwan; and vigorously promote the development of the whole chain of science and technology services in this field We will increase investment in applied R & D institutions, enterprises and projects with better prospects for industrialization Encourage and support one belt, one road of biological and new medicine enterprises To give full play to the "advantages of free trade", the Municipal Science and Technology Bureau, together with the municipal entry exit inspection and Quarantine Bureau, has jointly built a public service platform for biosafety risk assessment of entry-exit special articles, simplifying the import and export process of biological and new medical special biological products We will encourage "mass innovation and entrepreneurship" to build Xiamen into a city of innovation and entrepreneurship for small and micro enterprises in biology and new medicine; we will build a space of innovation and entrepreneurship for biology and new medicine in Haicang District to allow cross-strait youth innovation and cooperation The number is boring, and we hope to have a bright future: it is expected that by 2020 and strive to advance to 2018, the city's biological and new pharmaceutical industry will achieve the overall development goal of "1111", that is, to build a national level biomedical industry base, 10 national scientific research platforms, cultivate more than 10 billion yuan enterprises, and achieve a total industrial output value of 100 billion yuan These are all "made in Xiamen" high-end gene detection products Xiamen Eide Biomedical Technology Co., Ltd focuses on R & D and production of high-end gene detection technology and products for cancer precision medicine It is 2-3 years ahead of similar products at home and abroad, with a market share of more than 70% The products are sold in large-scale in more than 40 countries and regions Ebola virus detection card is developed by Yingke Xinchuang (Xiamen) science and Technology Co., Ltd the detection time of Ebola virus rapid detection card is only 1 / 15 of the existing method, and the use conditions are simple The product is currently being evaluated in Sierra Leone at the invitation of who In China, one belt, one road, is being marketed in the world The products are listed in China and will be sold in countries and regions where the hepatitis E is high in the "one belt and one way" The two cervical cancer vaccine developed by the 2018-2020 partners is expected to be listed in 2018-2020, becoming the world's first cervical cancer vaccine